<DOC>
	<DOCNO>NCT00231400</DOCNO>
	<brief_summary>The Pompe Registry ongoing , international multi-center , strictly observational program track routine clinical outcome patient Pompe disease , irrespective treatment status . No experimental intervention involve ; patient Registry undergo clinical assessment receive care determine patient 's treating physician . The objective Registry : - To enhance understanding variability , progression , natural history key manifestation Pompe disease ; - To assist Pompe medical community development recommendation monitor patient report patient outcome help optimize patient care ; - To characterize describe Pompe disease population whole ; - To evaluate long-term effectiveness safety available treatment option include ERT ( Enzyme Replacement Therapy ) MyozymeÂ® .</brief_summary>
	<brief_title>Pompe Disease Registry</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Patient must confirm diagnosis Pompe disease , document GAA ( Glucosidase Alpha Acid ) enzyme deficiency GAA gene mutation There exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Glycogen Storage Disease Type II ( GSD-II )</keyword>
	<keyword>GSD-II</keyword>
	<keyword>Pompe Disease</keyword>
	<keyword>Pompe Disease ( late-onset )</keyword>
	<keyword>Acid Maltase Deficiency Disease</keyword>
	<keyword>Glycogenosis II</keyword>
</DOC>